These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37011487)

  • 1. HHLA2 immune-regulatory roles in cancer.
    Mortezaee K
    Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
    Wei Y; Ren X; Galbo PM; Moerdler S; Wang H; Sica RA; Etemad-Gilbertson B; Shi L; Zhu L; Tang X; Lin Q; Peng M; Guan F; Zheng D; Chinai JM; Zang X
    Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34244312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
    Bhatt RS; Berjis A; Konge JC; Mahoney KM; Klee AN; Freeman SS; Chen CH; Jegede OA; Catalano PJ; Pignon JC; Sticco-Ivins M; Zhu B; Hua P; Soden J; Zhu J; McDermott DF; Arulanandam AR; Signoretti S; Freeman GJ
    Cancer Immunol Res; 2021 Feb; 9(2):156-169. PubMed ID: 33229411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.
    Ying H; Xu J; Zhang X; Liang T; Bai X
    EBioMedicine; 2022 May; 79():103987. PubMed ID: 35439678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
    Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
    J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
    Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
    Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Importance of HHLA2 in Solid Tumors-A Review of the Literature.
    Kula A; Koszewska D; Kot A; Dawidowicz M; Mielcarska S; Waniczek D; Świętochowska E
    Cells; 2024 May; 13(10):. PubMed ID: 38786018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
    Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
    Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H7: A potential target for cancer immunotherapy.
    Su Q; Du J; Xiong X; Xie X; Wang L
    Int Immunopharmacol; 2023 Aug; 121():110403. PubMed ID: 37290327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HHLA2: An Emerging Immune Checkpoint for Cancer Immunotherapy.
    Cao Z; Wang Y; Cheng SC; He N
    J Leukoc Biol; 2024 Jul; ():. PubMed ID: 38973642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
    Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
    Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model.
    Ren X; Corrigan DT; Zang X
    STAR Protoc; 2022 Dec; 3(4):101818. PubMed ID: 36386885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
    Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
    Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
    Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
    Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
    Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
    [No Abstract]   [Full Text] [Related]  

  • 16. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
    Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.
    Palmer WH; Leaton LA; Campos Codo A; Crute B; Roest J; Zhu S; Petersen J; Tobin RP; Hume PS; Stone M; van Bokhoven A; Gerich ME; McCarter MD; Zhu Y; Janssen WJ; Vivian JP; Trowsdale J; Getahun A; Rossjohn J; Cambier J; Loh L; Norman PJ
    Sci Immunol; 2023 Jun; 8(84):eade5343. PubMed ID: 37390222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
    He Y; Liu S; Mattei J; Bunn PA; Zhou C; Chan D
    Drug Des Devel Ther; 2018; 12():981-986. PubMed ID: 29731605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.
    Zhao R; Chinai JM; Buhl S; Scandiuzzi L; Ray A; Jeon H; Ohaegbulam KC; Ghosh K; Zhao A; Scharff MD; Zang X
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9879-84. PubMed ID: 23716685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.